IGM Biosciences experienced a challenging first quarter in 2025, reporting a net loss of $52.892 million. This was largely driven by substantial impairment charges on long-lived assets totaling $21.889 million and a significant decrease in interest income. Operating expenses remained high, with research and development costs decreasing due to strategic restructuring, while general and administrative expenses saw a slight increase. The company's liquidity remains a key focus as it evaluates strategic alternatives.

IGM Biosciences, Inc. reported a net loss of $195.8 million for the year ended December 31, 2024, a significant improvement from the previous year's $246.4 million loss. The company's collaboration revenue increased, while operating expenses, particularly research and development, saw a notable decrease.

IGM Biosciences announced a strategic pivot to focus exclusively on autoimmunity during the third quarter. The company's cash runway is expected to fund operations into 2027. Clinical development of Imvotamab and IGM-2644 are underway.

IGM Biosciences reported collaboration revenue of $1.3 million, R&D expenses of $42.0 million, G&A expenses of $10.6 million, and a net loss of $47.9 million for the second quarter of 2024. Enrollment is complete in the aplitabart randomized colorectal cancer clinical trial, and the second dose cohort has been cleared in the imvotamab rheumatoid arthritis clinical trial.

IGM Biosciences reported a net loss of $49.8 million, or $0.83 per share, for the first quarter of 2024. The company's cash and investments totaled $293.8 million as of March 31, 2024. Enrollment targets were exceeded in the aplitabart randomized colorectal cancer clinical trial, and enrollment was completed in the first dose cohort of the imvotamab rheumatoid arthritis clinical trial.